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co-stimulator (ICOS) protein was expressed predominantly 
on CD4 and CD8 effector T cells but not on regulatory T 
cells (Treg). In contrast, mice left untreated or treated solely 
with CTLA-4 blockade harbored elevated ICOS+ Treg, a 
phenotype associated with highly suppressive activity. In 
conclusion, poxvirus-based active immunotherapy induced 
robust tumor infiltration by highly efficient effector T cells. 
Combination with CTLA-4 immune checkpoint block-
ade amplified this response resulting in synergistically 
improved efficacy. These hypothesis-generating data may 
help elucidate evidence of enhanced clinical benefit from 
combining CTLA-4 blockade with poxvirus-based active 
immunotherapy.
Keywords Active immunotherapy · Poxvirus · Modified 
Vaccinia Ankara (MVA) · Cancer · Anti-CTLA-4 · Immune 
checkpoint blockade
Abbreviations
CEA  Carcinoembryonic antigen
CI  Combination index
CTL  Cytotoxic T lymphocytes
CTLA-4  Cytotoxic T lymphocyte-associated 
antigen-4
CV-301  Poxvirus-based active immunotherapy 
targeting CEA and MUC-1
DPECs  Double-positive effector cells
EECs  Early effector cells
HER-2  Human epidermal growth factor  
receptor 2
HER2  Modified extracellular domain of 
HER-2 and two additional T helper 
epitopes
ICOS  Inducible T cell co-stimulator
IFN  Interferon
Abstract The dramatic clinical benefit of immune check-
point blockade for a fraction of cancer patients suggests 
the potential for further clinical benefit in a broader can-
cer patient population by combining immune checkpoint 
inhibitors with active immunotherapies. The anti-tumor 
efficacy of MVA-BN-HER2 poxvirus-based active immu-
notherapy alone or in combination with CTLA-4 check-
point blockade was investigated in a therapeutic CT26-
HER-2 lung metastasis mouse model. MVA-BN-HER2 
immunotherapy significantly improved the median over-
all survival compared to untreated controls or CTLA-4 
blockade alone (p < 0.001). Robust synergistic efficacy 
was achieved with the combination therapy (p < 0.01). 
Improved survival following MVA-BN-HER2 administra-
tion was accompanied by increased tumor infiltration by 
HER-2-specific cytotoxic T lymphocytes (CTL). These 
tumor-specific CTL had characteristics similar to antiviral 
CTL, including strong expression of activation markers 
and co-expression of IFNγ and TNFα. Combination with 
CTLA-4 blockade significantly increased the magnitude 
of HER-2-specific T cell responses, with a higher propor-
tion co-expressing TNFα and/or IL-2 with IFNγ. Further-
more, in mice treated with MVA-BN-HER2 (alone or in 
combination with CTLA-4 blockade), the inducible T cell 
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IL  Interleukin
KLRG1  Killer cell lectin-like receptor G1
mCRPC  Metastatic castration-resistant prostate 
cancer
MFI  Mean fluorescence intensity
mOS  Median overall survival
MPECs  Memory precursor effector cells
MUC-1  Mucin-1
MVA  Modified vaccinia Ankara
MVA-BN-HER2  Poxvirus-based active immunotherapy 
targeting HER-2
PAP  Prostatic acid phosphatase
PROSTVAC  Poxvirus-based active immunotherapy 
targeting PSA
PSMA  Prostate-specific membrane antigen
PSA  Prostate-specific antigen
SLECs  Short-lived effector cells
Teff  Effector T cells
TILs  Tumor-infiltrating lymphocytes
TNF  Tumor necrosis factor
Tregs  Regulatory T cells
Introduction
The recent success of immune checkpoint inhibitors for 
the treatment of cancer has rejuvenated the field of cancer 
immunotherapy. Ipilimumab (Yervoy), a humanized mono-
clonal antibody specific for cytotoxic T lymphocyte-associ-
ated antigen-4 (CTLA-4), was the first FDA-approved drug 
from this new class of cancer immunotherapies. In patients 
with metastatic melanoma, ipilimumab treatment improved 
median overall survival (mOS) by 3.6 months and gener-
ated a complete response rate with durable tumor regres-
sion in 10–20 % of patients [1, 2]. Even greater clinical 
benefit may be achieved by selectively accelerating and 
augmenting anticancer immune responses through combi-
nation with active cancer immunotherapy.
PROSTVAC, a poxvirus-based active immunotherapy 
targeting the prostate-specific antigen (PSA), resulted in 
an 8.5-month increase in the mOS (25.1 vs. 16.6 months, 
p = 0.0061) in a randomized, placebo-controlled Phase 
2 clinical trial of men with asymptomatic or minimally 
symptomatic castration-resistant metastatic prostate 
cancer (mCRPC) [3]. In a similar patient population, 
a Phase 1 trial of 30 subjects combined PROSTVAC 
immunotherapy with dose escalation of ipilimumab (1, 
3, 5 and 10 mg/kg per dose), which resulted in a mOS 
of 31.3 months for all groups combined [4–6]. Patients 
who received PROSTVAC plus 10 mg/kg ipilimumab 
had a mOS of 37.2 months, and there appeared to be a 
tail on the survival curve with 20 % of patients alive at 
80 months [6]. In addition, 58 % of chemotherapy-naïve 
subjects exhibited a PSA decline from baseline from the 
combination therapy [4].
Poxvirus-based active immunotherapies in additional 
cancer types are being investigated for clinical benefit as 
single-agent regimens, but clinical regimens exploring 
combinations with immune checkpoint inhibitors have 
not yet been initiated. For example, longer overall sur-
vival following treatment with CV-301, a poxvirus-based 
active immunotherapy which targets carcinoembryonic 
antigen (CEA) and mucin-1 (MUC-1), was observed com-
pared to contemporary controls in metastatic colon cancer 
(p < 0.0001) [7]. In addition, MVA-BN-HER2, a recom-
binant modified vaccinia Ankara (MVA) vector express-
ing a modified form of the extracellular domain of human 
epidermal growth factor receptor 2 (HER-2), is under 
development for the treatment of breast cancer. MVA-BN-
HER2 was well tolerated in two Phase 1 clinical trials and 
showed evidence of peripheral immune responses against 
HER-2 in more than two-thirds of subjects [8]. Evidence 
that anti-tumor efficacy is mediated by induction of HER-
2-specific tumor-infiltrating lymphocytes (TILs) was gen-
erated in preclinical studies using MVA-BN-HER2 immu-
notherapy [9].
In this report, the impact of combining MVA-BN-HER2 
active immunotherapy and CTLA-4 blockade on efficacy 
was evaluated in a therapeutic mouse tumor model. We 
then investigated the immune response profiles of periph-
eral and tumor-infiltrating T cells and identified character-
istics that correlated with anti-tumor efficacy.
Materials and methods
Animals, tumor cell lines, and reagents
The CT26 murine colon carcinoma cell line express-
ing human HER-2 (CT26-HER-2) was licensed from the 
Regents of the University of California [10]; the genetic 
profile matched the established CT26 cell line (Idexx Radil, 
Columbia, MO, USA). A master cell bank and working cell 
banks were generated, and each bank was tested positive 
for HER-2 expression by flow cytometry (data not shown). 
Each bank was tested for a comprehensive list of pathogens 
including mycoplasma by Idexx Radil and was pathogen 
free. Cells were maintained and used as previously pub-
lished [9].
Female BALB/c mice (6–8 weeks old, Simonsen Lab-
oratories, Gilroy, CA) were implanted i.v. with 5.0 × 104 
CT26-HER-2 cells in 300 µL DPBS, which forms tumors 
in the lungs. On days 3 and 17 mice were treated with 
200 µg of an antagonist anti-CTLA-4 antibody (Clone 
9D9, Mouse IgG2b, Bio X Cell, West Lebanon, NH) by i.p. 
injection of 100 µL PBS. In studies to test for synergy and 
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for the multicytokine functional assay, mice were treated 
with a dose titration of anti-CTLA-4 (200, 66, and 22 µg 
i.p. in 100 µL PBS) on days 3 and 17 or 4 and 18. On days 
4 and 18 mice were treated with 1.0 × 107 Inf.U MVA-
BN-HER2 in 7.1 µL by tail scarification (t.s.). MVA-BN-
HER2 (Bavarian Nordic, BN, Martinsried, Germany) is a 
modified vaccinia Ankara-based recombinant vector that 
encodes a modified form of the human epidermal growth 
factor receptor 2 (HER-2), referred to as HER2 [9]. The 
modified HER2 comprises the extracellular domains of 
HER-2 and contains two additional T helper epitopes to 
enhance immunogenicity [11]. The infectious unit titer 
(Inf.U/mL) of MVA-BN-HER2 was determined by flow 
cytometry [12]. Control mice were implanted with CT26-
HER-2 cells on day 1 and received no additional treatment. 
Six months after the primary CT26-HER-2 challenge, mice 
that rejected tumors were implanted with 5.0 × 104 CT26-
WT cells in 300 µL DPBS.
To assess tumor burden, mice were euthanized on day 
25 and lungs were weighed. In each group, 1–2 mice were 
euthanized and perfused with trypan blue (0.4 %, Medi-
atech, Inc., Manassas, VA) through the trachea; the lungs 
were collected, briefly submerged in hydrogen perox-
ide (30 %, EMD Millipore Corporation, Billerica, MA), 
washed in PBS, and photographed. For survival studies 
mice were euthanized at the first sign of distress. The BN 
Institutional Animal Care and Use Committee approved all 
animal procedures.
Flow cytometry
Mice were treated as described above, and whole blood 
was collected via tail vein on days 10/11, 24/25 or 38. A 
strong T cell response was measured at day 24/25, 1 week 
after the second virus treatment. Subsequent studies exam-
ined tumor tissue at this time point when mice from each 
treatment as well as the control were alive. On day 24 or 25 
whole blood was isolated by cardiac stick followed by col-
lection of spleens and lungs for flow cytometric analysis. 
Tissues of 4–8 individual mice were analyzed for surface 
stains; tissues were pooled for 4–10 mice per group for the 
multicytokine and degranulation functional assays. Spleno-
cytes were prepared by pressing the spleens between two 
frosted glass slides and lysing the red blood cells with ACK 
lysis buffer (Life Technologies, Grand Island, NY). Lungs 
and associated tumors were diced to ~1- to 2-mm3 pieces 
and further digested to single-cell suspensions for 1 h at 
37 °C in DMEM with 10 % FBS, 50 U/mL DNAse I and 
250 U/mL Collagenase I (Worthington Biochemical Corpo-
ration, Lakewood, NJ). Red blood cells in lungs and whole 
blood were lysed with RBC lysis buffer (eBioscience).
Antibodies against the following proteins were pur-
chased from BD Bioscience (San Jose, CA): CD3e 
(500A2), CD4 (RM4-5), CD8a (53-6.7), CD11c (HL3), 
CD44 (IM7), CD62L (MEL-14), CD107a (1D4B), 
interferon-γ (IFN-γ) (XMG1.2), killer cell lectin-like 
receptor G1 (KLRG1, 2F1); from BioLegend (San 
Diego, CA): CD3e (145-2C11), CD127 (A7R34), IFNγ 
(XMG1.2), interleukin 2 (IL-2) (JES6-5H4), tumor necro-
sis factor-α (TNFα) (MP6-XT22); and from eBiosci-
ence (San Diego, CA): CD25 (PC61.5), ICOS (7E.17G9), 
CD127 (A7R34), FoxP3 (FJK-16 s), and CD16/CD32 (93).
To identify degranulating, cytotoxic T cells, single-cell 
suspensions of splenocytes (2 × 106 cells/well) or tumor/
lungs (1 × 106 cells/well) were resuspended in RPMI-10 
(10 % FBS, 1 % Pen-strep, and 0.1 % β-mercaptoethanol) 
and restimulated overnight at 37 °C in the presence of 
anti-CD107a antibody and Golgi Stop (BD Bioscience) 
[13]. The following peptides were synthesized by and pur-
chased from JPT Peptide Technologies, Inc. (Acton, MA): 
MVA E3L and F2L (VGPSNSPTF and SPGAAGYDL, 
1 µM each), HER-2 p63 (TYLPTNASL, 1 µM), HER-2 
ECD overlapping peptide library (HER-2 OPL, 1 µM), and 
PSA (HPQKVTKFML, 1 µM) [9, 14–16]. Concanavalin A 
(ConA, MP Biomedicals, Santa Ana, CA) was used at 5 µg/
mL as a positive control. The next day, cells were washed, 
blocked with anti-CD16/CD32 antibodies, and stained for 
surface markers. Cells were then washed, fixed/permeabi-
lized with BD Cytofix/Cytoperm buffer, and stained intra-
cellularly for IFNγ.
Additional intracellular cytokine staining was performed 
on splenocytes as described above except the anti-CD107a 
antibody was omitted, Golgi Stop and Golgi Plug were 
added, and cells were stained intracellularly for IFNγ, IL-2, 
and TNFα.
Regulatory T cells (Tregs) were stained intracellularly 
for FoxP3 using the fixation/permeabilization buffers from 
eBioscience according to the manufacturer’s instructions.
All samples were acquired on the BD LSRII or Fortessa 
and analyzed using FlowJo version 9.6.2 (TreeStar Inc., 
Ashland, OR). For all flow cytometry graphs, the CD4+ 
and CD8+ T cells were gated on CD3+ lymphocytes.
Statistical analysis
Statistical analyses were performed as described in the fig-
ure legends using GraphPad Prism version 6.01 for Win-
dows (GraphPad Software, La Jolla, CA). For immunolog-
ical data, data shown are the mean and standard error of 
the mean (SEM). An analysis of variance (ANOVA) with 
Holm–Sidak multiple comparisons test was used to deter-
mine statistical significance between treatment groups.
Synergy with the combination therapy in CT26-HER-2 
challenged mice was determined by calculating the com-
bination index (CI) using the Chou–Talalay method and 
CompuSyn software (www.combosyn.com) [17]. The 
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method requires performing a dose titration of each therapy 
alone and in combination. The effect at each dose is defined 
as the fractional survival (fa) and is based on the mOS for 
each dose. Hundred days was considered long-term sur-
vival (fa ≈ 1). For example, with a mOS of 50 days, the 
fa = 0.5 (50 days/100 days). Multiple studies with the same 
treatment groups were pooled to determine the mOS. It was 
necessary to normalize the mOS with respect to the pooled 
control group to perform the analysis. CI < 1 indicates syn-
ergism, CI = 1 indicates additive effect, and CI > 1 indi-
cates antagonism.
Results
MVA‑BN‑HER2 combined with an anti‑CTLA‑4 
antibody eliminates tumors in an experimental lung 
metastasis model
To test whether the efficacy of MVA-BN-HER2 immu-
notherapy is augmented when combined with CTLA-4 
immune checkpoint inhibition, mice were treated with 
MVA-BN-HER2 alone or in combination with an anti-
CTLA-4 blocking antibody in a therapeutic HER-2+ exper-
imental lung metastasis model. The combination of active 
immunotherapy plus checkpoint inhibition significantly 
and synergistically improved overall survival compared to 
either therapy alone [Fig. 1a, p < 0.001 vs. anti-CTLA-4 
and p < 0.01 vs. MVA-BN-HER2; very strong synergy 
shown with a combination index (CI) < 0.001, see Sup-
plemental Table 1]. The mOS of the combination therapy 
was greater than 100 days, significantly longer than either 
MVA-BN-HER2 treatment (49.5 days) or anti-CTLA-4 
treatment (35 days) alone. In addition, more than half of 
the mice treated with the combination therapy (57 %) 
were still alive 100 days after tumor challenge, compared 
to 14 % of mice treated with MVA-BN-HER2 alone or 
8 % of mice treated with anti-CTLA-4 alone. Next we 
tested the longevity of the induced anti-tumor response 
and evaluated whether the response had spread to antigens 
not encoded by the poxvirus-based active immunotherapy 
(antigen spreading). A small subset of mice that success-
fully rejected the initial CT26-HER-2 lung metastasis were 
rechallenged with CT26-WT cells (not expressing HER-2) 




































































Fig. 1  Overall survival and anti-tumor efficacy with MVA-BN-
HER2 immunotherapy and CTLA-4 blockade. a Kaplan–Meier sur-
vival curves from the combined results of three independent studies. 
The median overall survival in control mice (30 days) was signifi-
cantly extended with anti-CTLA-4 treatment (35 days, **p < 0.01), 
MVA-BN-HER2 treatment (49.5 days, ***p < 0.001), and MVA-
BN-HER2+ anti-CTLA-4 combination therapy (>100 days, 
***p < 0.001). A log-rank test with Bonferroni correction was used 
to determine significance between groups. b Representative lungs 
from each group harvested at day 25 were stained with Trypan Blue. 
Healthy lung tissue appears blue, while tumors appear red and white. 
Scale bar 1 cm. c Lung weights from treated mice on day 25 com-
pared to naïve mice. A one-way ANOVA with Dunnett’s multiple 
comparisons test was used to determine significance between groups, 
****p < 0.0001
▸
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6 months after primary challenge. All rechallenged mice 
rejected the parental tumors, while naïve mice challenged 
with the same parental tumor cells had a mOS of 26 days 
(Supplemental Figure 1). These data demonstrate that long-
lasting immune responses and antigen spread (expansion of 
the T cell repertoire from HER-2 to other cancer antigens) 
had occurred and were potent enough to protect mice from 
challenge with non-HER-2-expressing tumors.
Lungs of identically treated mice were removed 25 days 
after tumor implantation and assessed for tumor burden by 
lung weight. As seen in Fig. 1b, c, lungs of control mice or 
anti-CTLA-4 treated mice had numerous visible tumors at 
day 25, and the average lung weight was more than dou-
bled compared to healthy naïve mice (p < 0.0001). In stark 
contrast, lungs of mice treated with MVA-BN-HER2 alone 
or in combination with anti-CTLA-4 appeared healthy with 
a similar appearance as the lungs of naïve unchallenged 
mice, and had no difference in lung weight (p > 0.99). 
These results highlight the benefit of MVA-BN-HER2 
treatment to increase survival and reduce tumor burden.
Poxvirus‑based immunotherapy results in a distinct 
effector T cell phenotype
We hypothesized that phenotypic and functional analy-
sis of the effector T cell responses at the predicted peak 
of treatment-induced activity, 1 week after the last treat-
ment cycle, would reveal differences that later manifest 
as improved overall survival. Therefore, phenotypes of 
peripheral (spleen and blood) and tumor-/lung-infiltrating T 
cells from each treatment cohort were evaluated on day 25 
by flow cytometry.
To determine whether there was a specific phenotype 
associated with MVA-BN-HER2 treatment that was aug-
mented in combination with CTLA-4 blockade, we first 
looked at memory and activation markers induced by the 
different treatments. Effector memory cells generated in 
response to virus stimulation can be classified based on their 
expression of CD127 (IL7-Rα) and KLRG1. The KLRG1− 
CD127+ subset is a long-lived memory precursor effector 
cell (MPEC) population, while the KLRG1+ CD127− sub-
set is known as short-lived effector cells (SLECs) [18]. The 
KLRG1+ CD127+ double-positive effector cells (DPECs) 
are believed to constitute a potent long-lived effector 
memory T cell subset [18, 19]. SLEC and DPEC CD8 T 
cell populations were detected in the lungs and peripheral 
tissue of mice following MVA-BN-HER2 administration, 
but not after anti-CTLA-4 treatment (Fig. 2a, b). Further 
analysis showed that the vast majority (>80 %) of both 
SLECS and DPECS were CD44hi CD62L− (Supplemental 
Figure 2). The quality of the response induced by poxvirus-
based immunotherapy was maintained by combination with 
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Fig. 2  Effector T cell populations after MVA-BN-HER2 immuno-
therapy and/or CTLA-4 blockade. a Schematic for characterization 
of cells and a representative example of CD127 and KLRG1 expres-
sion in the tumor/lungs at day 25. b CD8+ CD127− KLRG1+ short-
lived effector cells (SLECs) and c CD8+ CD127+ KLRG1+ double-
positive effector cells (DPECs). MPECS memory precursor effector 
cells, EECs early effector cells. n = 8 mice/group combined from two 
independent experiments. p < 0.05: * versus control, † versus anti-
CTLA-4, and # versus MVA-BN-HER2
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anti-CTLA-4, but it was not augmented by combination 
therapy. Hence, the characterization of these SLEC and 
DPEC T cell populations at this time point was valuable for 
monitoring productive immunity in response to poxvirus-
mediated immunotherapy.
Combination therapy enhanced the population 
of tumor antigen‑specific cytotoxic TILs
To determine whether the improved survival could be due 
to enhanced CTL function, antigen-specific cytotoxic T 
cell activity in the tumor/lungs and the periphery (spleen) 
was evaluated. MVA-BN-HER2 immunotherapy plus 
CTLA-4 checkpoint blockade led to a marked increase in 
the proportion of functional, HER-2-specific CD8 cyto-
toxic T cells infiltrating into tumor tissue (Fig. 3a). While 
MVA-BN-HER2 or anti-CTLA-4 therapy alone resulted in 
moderate induction of HER-2-specific CD8 TILs, there was 
no response in control mice. Of note, the HER-2-specific 
cytotoxic CD8 response was three- to fourfold higher in 
the tumor/lungs than in the spleen, while the virus-targeted 
response (i.e., stimulated by MVA-specific E3L and F2L 
peptides) alone or in combination with anti-CTLA-4 was 
similar in both tissues. Thus, HER-2-specific T cells pref-
erentially homed to the tumor, and the magnitude of HER-
2-specific CD8 TILs response correlated with the length of 
survival in the tumor model.
The degranulating cells that responded to either HER-2 
p63 or MVA restimulation were predominantly SLECs 
(Fig. 3b), suggesting that the effector memory functions 
associated with the viral response phenotype also charac-
terized cells responding to the HER-2 p63 antigen. Over-
all, anti-CTLA-4 monotherapy increased the cytotoxic 
CD8 TILs tenfold compared to mice that had received no 









































KLRG1+  CD127+ DPECs
KLRG1+  CD127- SLECs
KLRG1-   CD127+ MPECs







































































Fig. 3  Degranulating T cells in the tumor/lungs or spleen of mice 
treated with MVA-BN-HER2 and/or CTLA-4 blockade. a Virus 
(MVA E3L F2L) and tumor antigen (HER-2 p63) specific responses 
were measured in the tumor/lungs and spleen; tissue was pooled from 
4 mice/group. b Expression of KLRG1 and CD127 on the virus or 
HER-2 p63-degranulating (CD107a+ IFNγ+) cells from A. Pie charts 
are area-weighted to reflect the number of CD8+ CD107a+ IFNγ+ 
cells per million T cells
543Cancer Immunol Immunother (2016) 65:537–549 
1 3
treatment. However, MVA-BN-HER2 administration led to 
a 25-fold increase in numbers of HER-2-specific cytotoxic 
CD8 TILs compared to no treatment. This impact on HER-
2-specific cytotoxic CD8 TILs was augmented to a 75-fold 
increase over controls following combination of active 
MVA-BN-HER2 immunotherapy with CTLA-4 checkpoint 
blockade.
Combination therapy induces the expansion 
of polyfunctional CD8 T cells
The quality of the T cell response was further character-
ized by measuring IFNγ, TNFα, and IL-2 cytokine levels 
in stimulated splenic CD8+ T cells. In response to virus or 
HER2-p63 restimulation, a five- to tenfold increase in the 
magnitude of IFNγ+ T cells was found in mice treated with 
MVA-BN-HER2 compared to tumor-bearing mice that 
received no treatment (control) or CTLA-4 blockade alone, 
as shown by the relative size of the pie charts (Fig. 4a). The 
magnitude of the response to combination treatment was on 
average twofold larger as compared to the MVA-BN-HER2 
treatment group after HER2-p63 restimulation (p < 0.01). 
The significant increase in IFNγ production with the com-
bination therapy compared to MVA-BN-HER2 alone was 
observed only when splenocytes were restimulated with the 
tumor-specific antigen (HER2-p63) and not in response to 
restimulation with the poxvirus (MVA). Following MVA-






























































































































































































































































































































Fig. 4  Antigen-specific cytokine production in CD8 T cells in the 
spleen. a Cytokine production in the spleen of mice treated with 
MVA-BN-HER2 and/or CTLA-4 blockade. Pie charts are area-
weighted to reflect the number of CD8+ IFNγ+ cells per million T 
cells. b IFNγ, TNFα, and IL-2 subsets of cytokine+ T cells shown in 
a. c IFNγ MFI plotted for the subsets of cytokine+ T cells shown in 
A. Data combined from 5 experiments. In each experiment, spleno-
cytes of 4–10 mice/group were pooled. p < 0.05: * versus control, † 
versus anti-CTLA-4, and # versus MVA-BN-HER2
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antigen-specific cells was accompanied by a shift to a 
polyfunctional cytokine phenotype. For instance, CTLA-4 
blockade alone induced CD8 T cells that were predomi-
nantly IFNγ single positive cells (depicted in purple). 
In contrast, more than 50 % of the IFNγ positive cells in 
MVA-BN-HER2-treated animals also produced TNFα 
(depicted in green) or IL-2 (depicted in blue), and a sub-
set of those cells produced all three cytokines (depicted in 
orange). Combination treatment resulted in a statistically 
significant increase in this proportion of tumor antigen-
specific (HER2-p63) cytokine-producing effector cells 
(Fig. 4b). A significantly higher percentage of the IFNγ+ 
TNFα+ IL-2+ or IFNγ+ TNFα+ polyfunctional HER-2 spe-
cific T cells were observed for the combination therapy as 
compared to MVA-BN-HER2 alone. This increase was spe-
cific for the HER-2 tumor antigen and was not observed in 
response to poxvirus-specific restimulation (MVA). Exami-
nation of the levels of IFNγ production from each of these 
CD8 T cell subsets was quantified by the mean fluorescence 
intensity (MFI) of each functional phenotype (Fig. 4c). On 
a per cell basis, polyfunctional cells produced more IFNγ 
than single positive cells. Overall, the cytokine profiles 
indicate that the functional quality of the tumor antigen-
specific T cell response, in addition to the magnitude of the 
tumor-specific T cell response, is augmented even further 
by the combination of active immunotherapy plus CTLA-4 
checkpoint blockade.
Poxvirus‑based active immunotherapy results 
in markedly improved Teff to Treg ratios within the 
tumor microenvironment
The expression profiles of the inducible T cell co-stimulatory 
(ICOS) molecule were of particular interest because this T 
cell activation marker is known to increase on CD4+ T cells 
within the tumor and periphery following anti-CTLA-4 treat-
ment [20]. CD4+ T cells exhibited elevated ICOS expression 
in the tumor/lungs of untreated controls and all treatment 
groups compared to naïve, tumor-free mice (Fig. 5a, b). 
Therefore, ICOS expression was induced on CD4+ T cells 
by the presence of the tumor without any treatment. Addition 
of the anti-CTLA-4 antibody alone raised ICOS expression 
to an even higher percentage of CD4+ T cells. Interestingly, 
ICOS levels were somewhat reduced on CD4+ T cells fol-
lowing MVA-BN-HER2 treatment compared to untreated 
controls, but were again higher when MVA-BN-HER2 was 
combined with CTLA-4 blockade. The increase in ICOS on 
CD4+ T cells was most prominent within the tumor/lungs, 
but elevated levels were also detected in the periphery of the 
treated groups but not in the control, tumor-bearing mice. 
Therefore, although differences in ICOS expression on 
CD4+ T cells were observed, they were not alone character-
istic of protective anti-tumor immune responses.
Analysis of CD8 T cells revealed that in the tumor/lungs 
ICOS expression showed the highest increases in MVA-
BN-HER2-treated mice irrespective of CTLA-4 treatment 
(Fig. 5c). In the blood and spleen, ICOS expression was 
consistently elevated on CD8+ T cells of mice treated with 
MVA-BN-HER2 in combination with anti-CTLA-4, com-
pared to control or anti-CTLA-4 treated mice. Thus, while 
the percentage of ICOS+ CD8+ T cells was significantly 
higher in the periphery with combination treatment, the 
responses observed in the tumor were similar in MVA-BN-
HER-2-treated groups irrespective of anti-CTLA-4 treat-
ment. This demonstrates that the poxvirus-based immuno-
therapy drives the quality of the induced immune response.
Elevated ICOS expression on CD4+ T cells characterizes 
the activation of effector cells (Teff) as well as highly sup-
pressive Tregs [21, 22]. We therefore examined which class 
of CD4+ T cells expressed ICOS in the different treatment 
groups (Fig. 6a). ICOS was elevated on FoxP3− Teff cells 
but not Tregs following MVA-BN-HER2 treatment (Fig. 6b, 
c), and ICOS was even more pronounced on FoxP3− Teff 
cells following combination therapy (Fig. 6c). This resulted 
in a marked increase in the ratio of both CD4+ and CD8+ 
ICOS+ Teff to ICOS
+ Tregs in the tumor/lungs and periphery 
in mice receiving MVA-BN-HER2 treatment compared to 
control mice (Fig. 6d, e). In contrast, in tumor-bearing con-
trol mice and mice treated only with anti-CTLA-4 where 
tumor burden was high, ICOS expression was increased 
on both FoxP3+ Tregs and FoxP3
− Teff cells (Fig. 6b, c). 
Overall, the high ICOS+ Teff to ICOS
+ Treg ratio induced 
by MVA-BN-HER2 alone or in combination with CTLA-4 
blockade likely reflects a more effective immune response 
and correlated with strong anti-tumor efficacy.
Discussion
We found that combining the poxvirus-based active immu-
notherapy with CTLA-4 checkpoint blockade strongly syn-
ergized to increase overall survival in a therapeutic mouse 
tumor model. In this combination, the poxvirus-based 
active immunotherapy drove the quality of the response, 
which was characterized by highly activated polyfunctional 
T cells; this T cell phenotype was further amplified by 
CTLA-4 treatment.
Treatment with MVA-BN-HER2, but not anti-CTLA-4 
alone, led to a dramatic increase of KLRG1 expression on 
CD8 T cells which were categorized with CD127/IL-7Rα 
expression as short-lived effector cells (SLECs, KLRG1+ 
CD127−) or an effector-like memory subset of double-
positive effector cells (DPECs, KLRG1+ CD127+) [19]. 
Induction of SLECs and DPECs was driven by the poxvi-
rus-based immunotherapy and was not further expanded 
in the combination therapy group. The SLEC and DPEC 
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phenotypes were also identified in mice treated with PROS-
TVAC and MVA poxvirus-based active immunotherapies 
[23, 24]. Interestingly, the SLEC and DPEC populations 
described here expanded for both virus-specific and HER-
2-specific degranulating T cells. This indicates that the 
effector characteristics associated with the viral response 
also defined the T cells responding to the encoded HER-2 
tumor-associated antigen. It may therefore be possible to 
identify poxvirus-induced T cells responding to the inserted 
tumor antigens in patients treated with poxvirus-based 
active immunotherapy by including virally induced mark-
ers in phenotyping panels [25].
The quality of the T cell responses is often assessed 
by the profile of cytokines produced upon activation, 
with co-expression of multiple cytokines defining more 
active effector cells [26]. Examination of a multicytokine 
profile of IFNγ, TNFα, and IL-2 revealed that poxvirus 
immunotherapy promoted co-expression of cytokines 
on CD8 T cells. This expansion in polyfunctional T 
cells was present in response to both the virus and the 
tumor antigen. Combination treatment with CTLA-4 
blockade significantly increased the number of IFNγ+ 
TNFα+ IL-2+ triple-positive and IFNγ+ TNFα+ double-
positive cells specific for the HER-2 tumor antigen but 
not the poxvirus vector (MVA), and this correlated with 
increased mOS. Furthermore, the magnitude of HER-
2-specific cytotoxic activity was increased in TILs of 
combination-treated animals.
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Fig. 5  ICOS expression on CD4+ and CD8+ T cells. a Representa-
tive example of ICOS expression on CD4+ and CD8+ T cells in the 
tumor/lungs at day 25. b ICOS expression on CD4+ T cells in the 
tumor/lungs, spleen, and blood. c ICOS expression on CD8+ T cells. 
n = 8 mice/group combined from two independent experiments. 
p < 0.05: * versus control, † versus anti-CTLA-4, and # versus MVA-
BN-HER2
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ICOS is expressed on activated T cells as a positive co-
stimulatory molecule, and its expression on peripheral T 
cells may provide a biomarker for therapeutic benefit with 
anti-CTLA-4 therapy [20, 27–29]. Our results revealed 
that treatment with CTLA-4 blockade augmented the num-
ber of ICOS+ CD4+ T cells but not ICOS+ CD8+ T cells 
in the tumor, blood, and spleen. In contrast, MVA-BN-
HER2 treatment was generally accompanied by an expan-
sion of ICOS+ CD8+ T cells, but this population was not 
further increased with CTLA-4 blockade. Though ICOS 
expression alone did not reveal the additional benefit of 
combining poxvirus immunotherapy with checkpoint inhi-
bition, these data suggest that higher expression of ICOS 
on effector cell populations may correlate with improved 
survival.
Importantly, poxvirus-based immunotherapy, alone or in 
combination with anti-CTLA-4 blockade, led to an increase 
in the ICOS+ Teff to ICOS
+ Treg ratio. This shift in the 
ICOS+ Teff to ICOS
+ Treg ratio was most pronounced at the 
tumor site, but it was also apparent in the spleen and blood. 
Unlike earlier reports, the Teff/Treg ratio did not increase 
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Fig. 6  ICOS expression on effector and regulatory T cells. a Repre-
sentative example of ICOS and FoxP3 expression in the tumor/lungs 
at day 25. b ICOS expression on FoxP3+ Tregs. c ICOS expression on 
FoxP3− CD4 T cells. d CD4 ICOS+ Teff to ICOS
+ Treg ratio (CD4
+ 
ICOS+ FoxP3−/CD4+ ICOS+ FoxP3+) and e CD8 ICOS+ Teff to 
ICOS+ Treg ratio (CD8
+ ICOS+/CD4+ ICOS+ FoxP3+). n = 8 mice/
group combined from two independent experiments. p < 0.05: * ver-
sus control, † versus anti-CTLA-4, and # versus MVA-BN-HER2
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there was a modest increase in overall survival (5 days). 
This may be due to a couple of factors. First, when the 
ICOS+ Teff to ICOS
+ Treg ratio was measured mice receiv-
ing CTLA-4 blockade alone had a large tumor burden, thus 
the shift in ICOS+ Teff to ICOS
+ Treg populations may no 
longer have been apparent. Second, the isotype of the anti-
CTLA-4 antibody is critical for the Treg depleting activity 
of the anti-CTLA-4 antibody [33]. The IgG2a isotype, but 
not the IgG2b isotype of the anti-CTLA-4 antibody used in 
the present study, led to selective reduction of intratumoral 
Tregs [33]. Previous studies have shown that combining 
MVA-BN-HER2 with Treg depletion further increased the 
mOS compared to MVA-BN-HER2 alone [9]. Therefore, 
combining MVA-BN-HER2 with an anti-CTLA-4 antibody 
with Treg depleting properties may lead to an even higher 
ICOS+ Teff to ICOS
+ Treg ratio and could potentially further 
enhance the efficacy of the combination therapy.
Antigen spread is the development of novel immune 
responses against target antigens expressed by the patient’s 
own tumor. Antigen spread responses are thought to be a 
crucial component of successful immunotherapy as they 
expand the anticancer immune repertoire beyond the ini-
tially targeted antigen. Rechallenge experiments with non-
HER-2-expressing tumors demonstrated that the immune 
responses were durable and were accompanied by antigen 
spread to additional tumor antigens. These data corrobo-
rate previous preclinical findings targeting HER-2, PSA, 
or CEA [9, 23, 34]. More importantly, antigen spread 
responses were also detected in clinical studies in 68 % of 
patients treated with PROSTVAC [35]. Immune responses 
to additional tumor antigens included PSMA (prostate-spe-
cific membrane antigen), PAP (prostatic acid phosphatase), 
MUC-1, and Brachyury [4, 36].
The present study was performed in mice where human 
HER-2 is not a self-antigen, and immune responses could 
be lower in a tolerant model. Anti-tumor efficacy and 
immune responses were demonstrated in transgenic mice 
expressing human CEA as a self-antigen using CEA-
targeted poxvirus-based active immunotherapy [37, 38]. 
Furthermore, when these poxvirus-based immunother-
apy candidates were used in combination with CTLA-4 
blockade, increased lymphocyte proliferation, IFNγ pro-
duction, and T cell avidity resulted in tumor rejection 
through immune responses to self-antigens in tolerant 
mouse models [39–41]. Our present study further charac-
terized the effect of combination therapy by investigating 
the magnitude and quality of TILs and peripheral lympho-
cytes. Our examination of viral and tumor antigen-specific 
responses revealed that the effector T cell characteristics 
associated with the viral response also defined the T cells 
responding to the encoded HER-2 tumor antigen and were 
further augmented in combination with CTLA-4 block-
ade. Thus, the preclinical data generated here provide 
hypothesis-generating evidence for elucidating the poten-
tial correlates of improved T cell effector responses result-
ing from combination poxvirus-based immunotherapy plus 
CTLA-4 checkpoint blockade.
In the clinic, monotherapy with PROSTVAC, a PSA-
targeted poxvirus-based active immunotherapy, signifi-
cantly extended the mOS from 16.6 to 25.1 months in 
patients with metastatic castration-resistant prostate can-
cer [3]. Ipilimumab alone provided a nonsignificant 1.2-
month improvement in overall survival compared to the 
placebo group in a Phase 3 trial of patients with prostate 
cancer [42]. Combining PROSTVAC with CTLA-4 block-
ade in a similar patient population resulted in an encourag-
ing mOS of 31.3 months in a Phase 1 study of fixed dose 
PROSTVAC with a dose escalation of Ipilimumab [3, 5, 6]. 
Of note, 20 % of patients treated with the highest dose of 
ipilimumab were still alive at 80 months [6]. Importantly, 
immune-related adverse events commonly associated with 
immune checkpoint inhibition were not exacerbated by 
combination with PROSTVAC immunotherapy [4]. Thus, 
the data from this work elucidating potential immunologic 
correlates for improved anti-tumor response in preclini-
cal models together with a suggestion of improved over-
all survival in the clinic support further clinical investiga-
tion of combination poxvirus-based active immunotherapy 
together with CTLA-4 immune checkpoint inhibition in 
prostate cancer and other cancers.
Conclusion
In summary, we showed that combination of poxvirus-
based active immunotherapy with CTLA-4 blockade 
resulted in synergistic anti-tumor efficacy. Functional and 
phenotypic characteristics of the immune response were 
driven by the poxvirus-based active immunotherapy and 
the antigen-specific effector T cell responses were further 
amplified by CTLA-4 blockade. These data provide evi-
dence that may translate into the potential immunologic 
correlates of productive anticancer immunity and clinical 
benefit resulting from poxvirus-based active immunother-
apy combined with CTLA-4 immune checkpoint inhibition.
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